Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Lung Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Liver Failure 1HRD Cancer 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Drug-Related Side Effects and Adverse Reactions 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

trastuzumab deruxtecan 1sacituzumab govitecan 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × sacituzumab govitecan × 30 days × Clear all
NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Recruiting
70 enrolled
Breast

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon ⚡